Spruce Biosciences, Inc. Common Stock (SPRB PINK) stock market data APIs
$118.1544
1.56(1.3%)
as of November 6, 2025
Try our APIs with
free plan!
Spruce Biosciences, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Prev. Close
118.1544
Open
119.7141
High
119.7141
Low
113.858
52 wk Range
7-3228.75
Market Cap
127 M
Shares Outstanding
1 066 K
Revenue
1 299 K
EPS
-3.5
Beta
3.493
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Spruce Biosciences, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Spruce Biosciences, Inc. Common Stock data using free add-ons & libraries
Get Spruce Biosciences, Inc. Common Stock Fundamental Data
Spruce Biosciences, Inc. Common Stock Fundamental data includes:
- Net Revenue: 1 299 K
- EBITDA: -50 634 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-08
- EPS/Forecast: -0.255
Get Spruce Biosciences, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spruce Biosciences, Inc. Common Stock News
New
Stocks making the biggest moves premarket: Trilogy Metals, Aehr Test Systems, Dollar Tree and more
Check out the companies making headlines before the bell. Trilogy Metals — U.S.-listed shares of the Canadian minerals explorer soared more than 222% after the White House said it would take a stake...
Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy
[Modern Medicine Laboratory: Diverse Team of Multi-Ethnic Young Scientists Analysing Test Samples. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs, Doing Research...
Spruce Biosciences resumes Nasdaq trading; shares up over 40%
* Spruce Biosciences (OTC:SPRB [https://seekingalpha.com/symbol/SPRB]) will resume trading on Nasdaq, September 15, 2025. * The company focuses on developing therapies for neurological disorders w...
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
Illumina (ILMN) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.36 per share a year ago. These figures are...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
